• Biohaven's Acute Migraine Drug Bests Placebo in Prevention Study

    1 month ago - By Xconomy

    Biohaven Pharmaceutical's FDA-approved pill to treat migraine attacks is showing that it can prevent such headaches too. According to preliminary results from a late-stage trial released Monday, the Biohaven drug beat a placebo at reducing the average number of days per month patients with chronic and episodic migraine experienced the debilitating condition. The FDA OK'd the drug, rigemepant , as a treatment for acute migraine about a month ago. Based on the new results released Monday, the New Haven, CT-based company plans to ask regulators to approve expansion of the drug's approval to...
    Read more ...